TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Comparative Study Evaluating the Immunogenicity and Safety of MeMuRu-OKA Vaccine and Measles-mumps-rubella Vaccine (Priorix™) Co-administered With Varicella Vaccine (Varilrix™) in Children Primed With Measles-mumps-rubella Vaccine
Brief Summary: As measles-mumps-rubella (MMR) vaccination is established as routine childhood practice in most industrialised countries and varicella vaccination is now being introduced in many countries during the second year of life, a combined measles-mumps-rubella-varicella vaccine was developed for administration convenience and improved compliance to vaccination. To account for situations where children have received a first dose of MMR vaccine without varicella, this study will evaluate the effect of the combined measles-mumps-rubella-varicella vaccine given in place of the second dose of MMR vaccine. A second dose of the monovalent varicella vaccine will be given to all children participating to this trial since there is a current debate on the need of a second dose to induce a full protection against varicella.


Options:
A: Arm Label: Arm 1; Type: EXPERIMENTAL; Interventions: Biological: Varicella-zoster vaccine | Arm Label: Arm 2; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo | Intervention Type: BIOLOGICAL; Name: Varicella-zoster vaccine; Assigned to Arm(s): Arm 1 | Intervention Type: BIOLOGICAL; Name: Placebo; Assigned to Arm(s): Arm 2
B: Intervention Type: BIOLOGICAL; Name: MeMuRu-OKA (study vacc); Assigned to Arm(s): N/A | Intervention Type: BIOLOGICAL; Name: MMR, Varicella vacc (control); Assigned to Arm(s): N/A
C: Arm Label: ProQuad®; Type: EXPERIMENTAL; Interventions: Biological: ProQuad® | Intervention Type: BIOLOGICAL; Name: ProQuad®; Assigned to Arm(s): ProQuad®
D: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Biological: Comparator: VAQTA™ (Hepatitis A vaccine), Biological: Comparator: ProQuad™ (Measles, Mumps, Rubella and Varicella vaccine), Biological: Comparator: Prevnar™ (Pneumococcal 7-Valent Conjugate vaccine) | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Biological: Comparator: VAQTA™ (Hepatitis A vaccine), Biological: Comparator: ProQuad™ (Measles, Mumps, Rubella and Varicella vaccine), Biological: Comparator: Prevnar™ (Pneumococcal 7-Valent Conjugate vaccine) | Intervention Type: BIOLOGICAL; Name: Comparator: VAQTA™ (Hepatitis A vaccine); Assigned to Arm(s): 1, 2 | Intervention Type: BIOLOGICAL; Name: Comparator: ProQuad™ (Measles, Mumps, Rubella and Varicella vaccine); Assigned to Arm(s): 1, 2 | Intervention Type: BIOLOGICAL; Name: Comparator: Prevnar™ (Pneumococcal 7-Valent Conjugate vaccine); Assigned to Arm(s): 1, 2

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Bread Trial: a Demonstration Trial to Show Effects of Fortification of Food With Both Folic Acid and Vitamin B12
Brief Summary: In the Netherlands fortification of food products is not yet mandatory. One of the major arguments of the Dutch Health Council to advise against mandatory fortification is the possibility of masking of a vitamin B12 deficiency. A possible solution to overcome the possibility of masking is: fortification of foods with both folic acid and vitamin B12. In this study we want to assess the effects of this fortification strategy on markers of folate and vitamin B12 status.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: PAL-40 Active | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: PAL-40 Placebo | Intervention Type: DRUG; Name: PAL-40 Active; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: PAL-40 Placebo; Assigned to Arm(s): 2
B: Intervention Type: DRUG; Name: Aspirin; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Folate; Assigned to Arm(s): N/A
C: Intervention Type: PROCEDURE; Name: consumption of fortified bread; Assigned to Arm(s): N/A
D: Intervention Type: DRUG; Name: Folic acid; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Vitamin B12; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Vitamin B6; Assigned to Arm(s): N/A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Bread Trial: a Demonstration Trial to Show Effects of Fortification of Food With Both Folic Acid and Vitamin B12
Brief Summary: In the Netherlands fortification of food products is not yet mandatory. One of the major arguments of the Dutch Health Council to advise against mandatory fortification is the possibility of masking of a vitamin B12 deficiency. A possible solution to overcome the possibility of masking is: fortification of foods with both folic acid and vitamin B12. In this study we want to assess the effects of this fortification strategy on markers of folate and vitamin B12 status.


Options:
A: Arm Label: Zinc-fortified bread (10 mg zinc/d); Type: EXPERIMENTAL; Interventions: Dietary Supplement: Zinc-fortified bread, Dietary Supplement: Placebo supplement | Arm Label: Zinc fortified bread (20 mg zinc/d); Type: EXPERIMENTAL; Interventions: Dietary Supplement: Zinc-fortified bread, Dietary Supplement: Placebo supplement | Arm Label: Zinc supplemented group; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Zinc supplement, Dietary Supplement: Non-fortified bread | Arm Label: Non-fortified group; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Non-fortified bread, Dietary Supplement: Placebo supplement | Intervention Type: DIETARY_SUPPLEMENT; Name: Zinc-fortified bread; Assigned to Arm(s): Zinc fortified bread (20 mg zinc/d), Zinc-fortified bread (10 mg zinc/d) | Intervention Type: DIETARY_SUPPLEMENT; Name: Zinc supplement; Assigned to Arm(s): Zinc supplemented group | Intervention Type: DIETARY_SUPPLEMENT; Name: Non-fortified bread; Assigned to Arm(s): Non-fortified group, Zinc supplemented group | Intervention Type: DIETARY_SUPPLEMENT; Name: Placebo supplement; Assigned to Arm(s): Non-fortified group, Zinc fortified bread (20 mg zinc/d), Zinc-fortified bread (10 mg zinc/d)
B: Intervention Type: PROCEDURE; Name: consumption of fortified bread; Assigned to Arm(s): N/A
C: Arm Label: Folic acid; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Folic acid | Arm Label: L-5-MTHF; Type: EXPERIMENTAL; Interventions: Dietary Supplement: L-5-MTHF | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: Folic acid; Assigned to Arm(s): Folic acid | Intervention Type: DIETARY_SUPPLEMENT; Name: L-5-MTHF; Assigned to Arm(s): L-5-MTHF | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo
D: Intervention Type: DRUG; Name: Aspirin; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Folate; Assigned to Arm(s): N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Phase III, Randomised, Double-blind, Stratified Comparative, Placebo Controlled, Parallel Group, Multi-centre Study to Assess the Effect of Deep Subcutaneous Injections of Lanreotide Autogel 120mg Administered Every 28 Days on Tumour Progression Free Survival in Patients With Non-functioning Entero-pancreatic Endocrine Tumour
Brief Summary: The study will compare the difference between lanreotide Autogel and placebo on progression free survival in patients who have an endocrine tumour in the pancreas or intestines.


Options:
A: Arm Label: Lanreotide Autogel (Somatuline Depot) 120 mg; Type: EXPERIMENTAL; Interventions: Drug: Lanreotide | Arm Label: Placebo (DB) and lanreotide Autogel 120 mg in IOL and LTOLE; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Lanreotide; Assigned to Arm(s): Lanreotide Autogel (Somatuline Depot) 120 mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo (DB) and lanreotide Autogel 120 mg in IOL and LTOLE
B: Arm Label: lanreotide (Autogel formulation); Type: EXPERIMENTAL; Interventions: Drug: lanreotide (Autogel formulation) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: lanreotide (Autogel formulation); Assigned to Arm(s): lanreotide (Autogel formulation) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Arm I (octreotide acetate and bevacizumab); Type: EXPERIMENTAL; Interventions: Biological: Bevacizumab, Other: Laboratory Biomarker Analysis, Drug: Octreotide Acetate | Arm Label: Arm II (octreotide acetate and recombinant interferon alfa-2b); Type: EXPERIMENTAL; Interventions: Other: Laboratory Biomarker Analysis, Drug: Octreotide Acetate, Biological: Recombinant Interferon Alfa-2b | Intervention Type: BIOLOGICAL; Name: Bevacizumab; Assigned to Arm(s): Arm I (octreotide acetate and bevacizumab) | Intervention Type: OTHER; Name: Laboratory Biomarker Analysis; Assigned to Arm(s): Arm I (octreotide acetate and bevacizumab), Arm II (octreotide acetate and recombinant interferon alfa-2b) | Intervention Type: DRUG; Name: Octreotide Acetate; Assigned to Arm(s): Arm I (octreotide acetate and bevacizumab), Arm II (octreotide acetate and recombinant interferon alfa-2b) | Intervention Type: BIOLOGICAL; Name: Recombinant Interferon Alfa-2b; Assigned to Arm(s): Arm II (octreotide acetate and recombinant interferon alfa-2b)
D: Arm Label: 177Lu-DOTA0-Tyr3-Octreotate; Type: EXPERIMENTAL; Interventions: Drug: Octreotide LAR, Drug: 177Lu-DOTA0-Tyr3-Octreotate | Arm Label: Octreotide LAR; Type: ACTIVE_COMPARATOR; Interventions: Drug: Octreotide LAR | Intervention Type: DRUG; Name: Octreotide LAR; Assigned to Arm(s): 177Lu-DOTA0-Tyr3-Octreotate, Octreotide LAR | Intervention Type: DRUG; Name: 177Lu-DOTA0-Tyr3-Octreotate; Assigned to Arm(s): 177Lu-DOTA0-Tyr3-Octreotate

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Genomics to Combat Resistance Against Antibiotics in Community-Acquired LRTI in Europe: GRACE. Workpackage 8. An Observational Study of Cough / Lower Respiratory Tract Infection (LRTI) in Primary Care
Brief Summary: The overall objective of GRACE is to combat the resistance of drugs that kill bacteria and other germs (antimicrobial) through integrating centres of research excellence and using the study of the entire DNA in a cell (genomics) to most appropriately investigate and manage community-acquired LRTI.

Grace-01 is the first study to be undertaken as part of GRACE and the aims of this study are to describe the presentation, diagnosis, investigation, management and outcomes for people with cough / chest infection in general medical practice in 13 primary care networks in 12 countries in Europe.


Options:
A: Intervention Type: BEHAVIORAL; Name: Educational intervention; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Educational intervention program; Assigned to Arm(s): N/A
B: Arm Label: e-POCT; Type: EXPERIMENTAL; Interventions: Other: Management of febrile children using e-POCT | Arm Label: ALMANACH; Type: ACTIVE_COMPARATOR; Interventions: Other: Management of febrile children using ALMANACH | Arm Label: Routine practice; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Management of febrile children using e-POCT; Assigned to Arm(s): e-POCT | Intervention Type: OTHER; Name: Management of febrile children using ALMANACH; Assigned to Arm(s): ALMANACH
C: N/A
D: Arm Label: Procalcitonin (PCT) group; Type: EXPERIMENTAL; Interventions: Other: Procalcitonin level, Other: Results of procalcitonin (PCT) level to treating clinician, Other: Provide procalcitonin guideline to treating clinician, Other: Telephone Visit | Arm Label: Usual Care group; Type: ACTIVE_COMPARATOR; Interventions: Other: Telephone Visit | Intervention Type: OTHER; Name: Procalcitonin level; Assigned to Arm(s): Procalcitonin (PCT) group | Intervention Type: OTHER; Name: Results of procalcitonin (PCT) level to treating clinician; Assigned to Arm(s): Procalcitonin (PCT) group | Intervention Type: OTHER; Name: Provide procalcitonin guideline to treating clinician; Assigned to Arm(s): Procalcitonin (PCT) group | Intervention Type: OTHER; Name: Telephone Visit; Assigned to Arm(s): Procalcitonin (PCT) group, Usual Care group

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: An Open, Randomized, Multi-centre Trial to Investigate the Effect of Anemia Correction on Cardiac Structure and Function in Patients With Early Diabetic Nephropathy
Brief Summary: This study will assess the effect of anemia correction with NeoRecormon on cardiac structure and function in patients with early diabetic nephropathy. The anticipated time on study treatment is 1-2 years and the target sample size is 100-500 individuals.


Options:
A: Intervention Type: DRUG; Name: Epoetin; Assigned to Arm(s): N/A
B: Arm Label: RO0503821 (1x/2 Weeks); Type: EXPERIMENTAL; Interventions: Drug: RO0503821 (1x/2 Weeks) | Arm Label: RO0503821 (1x/4 Weeks); Type: EXPERIMENTAL; Interventions: Drug: RO0503821 (1x/4 Weeks) | Arm Label: Epoetin (1-3x/Weeks); Type: ACTIVE_COMPARATOR; Interventions: Drug: Epoetin alfa or beta | Intervention Type: DRUG; Name: Epoetin alfa or beta; Assigned to Arm(s): Epoetin (1-3x/Weeks) | Intervention Type: DRUG; Name: RO0503821 (1x/2 Weeks); Assigned to Arm(s): RO0503821 (1x/2 Weeks) | Intervention Type: DRUG; Name: RO0503821 (1x/4 Weeks); Assigned to Arm(s): RO0503821 (1x/4 Weeks)
C: Arm Label: Early Epoetin Beta Therapy; Type: EXPERIMENTAL; Interventions: Drug: epoetin beta [NeoRecormon] | Arm Label: Late Epoetin Beta Therapy; Type: ACTIVE_COMPARATOR; Interventions: Drug: epoetin beta [NeoRecormon] | Intervention Type: DRUG; Name: epoetin beta [NeoRecormon]; Assigned to Arm(s): Early Epoetin Beta Therapy | Intervention Type: DRUG; Name: epoetin beta [NeoRecormon]; Assigned to Arm(s): Late Epoetin Beta Therapy
D: Arm Label: Group 1 (Early Epoetin Beta); Type: EXPERIMENTAL; Interventions: Drug: Epoetin beta | Arm Label: Group 2 (No/Late Epoetin Beta); Type: ACTIVE_COMPARATOR; Interventions: Drug: Epoetin beta | Intervention Type: DRUG; Name: Epoetin beta; Assigned to Arm(s): Group 1 (Early Epoetin Beta), Group 2 (No/Late Epoetin Beta)

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: An Open, Randomized, Multi-centre Trial to Investigate the Effect of Anemia Correction on Cardiac Structure and Function in Patients With Early Diabetic Nephropathy
Brief Summary: This study will assess the effect of anemia correction with NeoRecormon on cardiac structure and function in patients with early diabetic nephropathy. The anticipated time on study treatment is 1-2 years and the target sample size is 100-500 individuals.


Options:
A: Arm Label: Group 1 (Early Epoetin Beta); Type: EXPERIMENTAL; Interventions: Drug: Epoetin beta | Arm Label: Group 2 (No/Late Epoetin Beta); Type: ACTIVE_COMPARATOR; Interventions: Drug: Epoetin beta | Intervention Type: DRUG; Name: Epoetin beta; Assigned to Arm(s): Group 1 (Early Epoetin Beta), Group 2 (No/Late Epoetin Beta)
B: Arm Label: Epoetin alfa; Type: ACTIVE_COMPARATOR; Interventions: Drug: Epoetin Alfa | Arm Label: Darbepoetin alfa; Type: ACTIVE_COMPARATOR; Interventions: Drug: Darbepoetin alfa | Intervention Type: DRUG; Name: Epoetin Alfa; Assigned to Arm(s): Epoetin alfa | Intervention Type: DRUG; Name: Darbepoetin alfa; Assigned to Arm(s): Darbepoetin alfa
C: Arm Label: Epoetin Bio-Manguinhos; Type: EXPERIMENTAL; Interventions: Drug: Epoetin Alfa-BioManguinhos | Arm Label: EPO-BioSimilar; Type: ACTIVE_COMPARATOR; Interventions: Drug: Epoetin Alfa-BioSimilar | Intervention Type: DRUG; Name: Epoetin Alfa-BioManguinhos; Assigned to Arm(s): Epoetin Bio-Manguinhos | Intervention Type: DRUG; Name: Epoetin Alfa-BioSimilar; Assigned to Arm(s): EPO-BioSimilar
D: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Dynepo (Epoetin delta) | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Dynepo | Arm Label: 3; Type: ACTIVE_COMPARATOR; Interventions: Drug: Dynepo | Arm Label: 4; Type: ACTIVE_COMPARATOR; Interventions: Drug: Dynepo | Intervention Type: DRUG; Name: Dynepo (Epoetin delta); Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Dynepo; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Dynepo; Assigned to Arm(s): 3 | Intervention Type: DRUG; Name: Dynepo; Assigned to Arm(s): 4

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomized Study of Soy Protein and Effexor on Vasomotor Symptoms of Men With Prostate Cancer
Brief Summary: RATIONALE: Soy protein/isoflavones and venlafaxine may help relieve hot flashes in patients receiving hormone therapy for prostate cancer. It is not yet known whether soy protein/isoflavones are more effective than venlafaxine when given together or with a placebo in treating hot flashes.

PURPOSE: This randomized phase III trial is studying soy protein/isoflavones and venlafaxine to compare how well they work when given together or with a placebo in treating hot flashes in patients receiving hormone therapy for prostate cancer.


Options:
A: Arm Label: quetiapine; Type: EXPERIMENTAL; Interventions: Drug: quetiapine | Arm Label: escitalopram; Type: ACTIVE_COMPARATOR; Interventions: Drug: escitalopram | Intervention Type: DRUG; Name: quetiapine; Assigned to Arm(s): quetiapine | Intervention Type: DRUG; Name: escitalopram; Assigned to Arm(s): escitalopram
B: Arm Label: Methylphenidate add on to Mirtazapine; Type: EXPERIMENTAL; Interventions: Drug: Methylphenidate | Arm Label: Placebo add on to Mirtazapine; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Methylphenidate; Assigned to Arm(s): Methylphenidate add on to Mirtazapine | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo add on to Mirtazapine
C: Arm Label: Arm I - Placebo; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Placebo Powder, Drug: Placebo Pill | Arm Label: Arm II - Soy; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: oral soy protein/isoflavones powder, Drug: Placebo Pill | Arm Label: Arm III - Venlafaxine; Type: EXPERIMENTAL; Interventions: Drug: Venlafaxine, Dietary Supplement: Placebo Powder | Arm Label: Arm IV - Soy + Venlafaxine; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: oral soy protein/isoflavones powder, Drug: Venlafaxine | Intervention Type: DIETARY_SUPPLEMENT; Name: oral soy protein/isoflavones powder; Assigned to Arm(s): Arm II - Soy, Arm IV - Soy + Venlafaxine | Intervention Type: DRUG; Name: Venlafaxine; Assigned to Arm(s): Arm III - Venlafaxine, Arm IV - Soy + Venlafaxine | Intervention Type: DIETARY_SUPPLEMENT; Name: Placebo Powder; Assigned to Arm(s): Arm I - Placebo, Arm III - Venlafaxine | Intervention Type: DRUG; Name: Placebo Pill; Assigned to Arm(s): Arm I - Placebo, Arm II - Soy
D: Arm Label: Psilocybin; Type: EXPERIMENTAL; Interventions: Drug: Psilocybin, Drug: Niacin | Arm Label: Niacin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Psilocybin, Drug: Niacin | Intervention Type: DRUG; Name: Psilocybin; Assigned to Arm(s): Niacin, Psilocybin | Intervention Type: DRUG; Name: Niacin; Assigned to Arm(s): Niacin, Psilocybin

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomized Study of Soy Protein and Effexor on Vasomotor Symptoms of Men With Prostate Cancer
Brief Summary: RATIONALE: Soy protein/isoflavones and venlafaxine may help relieve hot flashes in patients receiving hormone therapy for prostate cancer. It is not yet known whether soy protein/isoflavones are more effective than venlafaxine when given together or with a placebo in treating hot flashes.

PURPOSE: This randomized phase III trial is studying soy protein/isoflavones and venlafaxine to compare how well they work when given together or with a placebo in treating hot flashes in patients receiving hormone therapy for prostate cancer.


Options:
A: Arm Label: quetiapine; Type: EXPERIMENTAL; Interventions: Drug: quetiapine | Arm Label: escitalopram; Type: ACTIVE_COMPARATOR; Interventions: Drug: escitalopram | Intervention Type: DRUG; Name: quetiapine; Assigned to Arm(s): quetiapine | Intervention Type: DRUG; Name: escitalopram; Assigned to Arm(s): escitalopram
B: Arm Label: Arm I (management of therapy complications); Type: EXPERIMENTAL; Interventions: Drug: venlafaxine, Other: questionnaire administration, Other: quality-of-life assessment | Arm Label: Arm II (placebo); Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo, Other: questionnaire administration, Other: quality-of-life assessment | Intervention Type: DRUG; Name: venlafaxine; Assigned to Arm(s): Arm I (management of therapy complications) | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Arm II (placebo) | Intervention Type: OTHER; Name: questionnaire administration; Assigned to Arm(s): Arm I (management of therapy complications), Arm II (placebo) | Intervention Type: OTHER; Name: quality-of-life assessment; Assigned to Arm(s): Arm I (management of therapy complications), Arm II (placebo)
C: Arm Label: Desipramine HCl; Type: EXPERIMENTAL; Interventions: Drug: Desipramine HCL | Intervention Type: DRUG; Name: Desipramine HCL; Assigned to Arm(s): Desipramine HCl
D: Arm Label: Arm I - Placebo; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Placebo Powder, Drug: Placebo Pill | Arm Label: Arm II - Soy; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: oral soy protein/isoflavones powder, Drug: Placebo Pill | Arm Label: Arm III - Venlafaxine; Type: EXPERIMENTAL; Interventions: Drug: Venlafaxine, Dietary Supplement: Placebo Powder | Arm Label: Arm IV - Soy + Venlafaxine; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: oral soy protein/isoflavones powder, Drug: Venlafaxine | Intervention Type: DIETARY_SUPPLEMENT; Name: oral soy protein/isoflavones powder; Assigned to Arm(s): Arm II - Soy, Arm IV - Soy + Venlafaxine | Intervention Type: DRUG; Name: Venlafaxine; Assigned to Arm(s): Arm III - Venlafaxine, Arm IV - Soy + Venlafaxine | Intervention Type: DIETARY_SUPPLEMENT; Name: Placebo Powder; Assigned to Arm(s): Arm I - Placebo, Arm III - Venlafaxine | Intervention Type: DRUG; Name: Placebo Pill; Assigned to Arm(s): Arm I - Placebo, Arm II - Soy

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Double-Blind, Placebo-Controlled Study of N-Acetyl Cysteine in Trichotillomania
Brief Summary: This is a 12-week, double-blind study of N-Acetyl Cysteine in the treatment of trichotillomania


Options:
A: Intervention Type: DRUG; Name: Methylphenidate; Assigned to Arm(s): N/A
B: Arm Label: N-Acetyl Cysteine; Type: ACTIVE_COMPARATOR; Interventions: Drug: N-Acetyl Cysteine | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: N-Acetyl Cysteine; Assigned to Arm(s): N-Acetyl Cysteine
C: Arm Label: N-acetylcysteine (NAC); Type: EXPERIMENTAL; Interventions: Drug: N-Acetylcysteine | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: N-Acetylcysteine; Assigned to Arm(s): N-acetylcysteine (NAC) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Naltrexone | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Naltrexone; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2

Answer: B